Adaptive Biotechnologies (ADPT) Competitors $7.38 +0.37 (+5.28%) Closing price 04/23/2025 04:00 PM EasternExtended Trading$7.36 -0.02 (-0.34%) As of 08:01 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock ADPT vs. PCVX, RYTM, PTCT, RNA, ACLX, RARE, ZLAB, AKRO, MRUS, and MORShould you be buying Adaptive Biotechnologies stock or one of its competitors? The main competitors of Adaptive Biotechnologies include Vaxcyte (PCVX), Rhythm Pharmaceuticals (RYTM), PTC Therapeutics (PTCT), Avidity Biosciences (RNA), Arcellx (ACLX), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Akero Therapeutics (AKRO), Merus (MRUS), and MorphoSys (MOR). These companies are all part of the "pharmaceutical products" industry. Adaptive Biotechnologies vs. Vaxcyte Rhythm Pharmaceuticals PTC Therapeutics Avidity Biosciences Arcellx Ultragenyx Pharmaceutical Zai Lab Akero Therapeutics Merus MorphoSys Vaxcyte (NASDAQ:PCVX) and Adaptive Biotechnologies (NASDAQ:ADPT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, community ranking, valuation, analyst recommendations, media sentiment, institutional ownership, earnings, dividends and profitability. Which has more risk & volatility, PCVX or ADPT? Vaxcyte has a beta of 1.26, indicating that its share price is 26% more volatile than the S&P 500. Comparatively, Adaptive Biotechnologies has a beta of 1.73, indicating that its share price is 73% more volatile than the S&P 500. Do analysts rate PCVX or ADPT? Vaxcyte currently has a consensus price target of $136.50, indicating a potential upside of 311.64%. Adaptive Biotechnologies has a consensus price target of $9.40, indicating a potential upside of 27.37%. Given Vaxcyte's stronger consensus rating and higher probable upside, analysts clearly believe Vaxcyte is more favorable than Adaptive Biotechnologies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vaxcyte 0 Sell rating(s) 0 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.10Adaptive Biotechnologies 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has preferable earnings and valuation, PCVX or ADPT? Adaptive Biotechnologies has higher revenue and earnings than Vaxcyte. Vaxcyte is trading at a lower price-to-earnings ratio than Adaptive Biotechnologies, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxcyteN/AN/A-$402.27M-$3.80-8.73Adaptive Biotechnologies$178.96M6.13-$159.49M-$1.09-6.77 Do insiders and institutionals have more ownership in PCVX or ADPT? 96.8% of Vaxcyte shares are held by institutional investors. Comparatively, 99.2% of Adaptive Biotechnologies shares are held by institutional investors. 3.1% of Vaxcyte shares are held by company insiders. Comparatively, 6.2% of Adaptive Biotechnologies shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Does the MarketBeat Community prefer PCVX or ADPT? Adaptive Biotechnologies received 43 more outperform votes than Vaxcyte when rated by MarketBeat users. However, 78.57% of users gave Vaxcyte an outperform vote while only 57.99% of users gave Adaptive Biotechnologies an outperform vote. CompanyUnderperformOutperformVaxcyteOutperform Votes5578.57% Underperform Votes1521.43% Adaptive BiotechnologiesOutperform Votes9857.99% Underperform Votes7142.01% Does the media prefer PCVX or ADPT? In the previous week, Vaxcyte had 17 more articles in the media than Adaptive Biotechnologies. MarketBeat recorded 19 mentions for Vaxcyte and 2 mentions for Adaptive Biotechnologies. Adaptive Biotechnologies' average media sentiment score of 1.52 beat Vaxcyte's score of 1.01 indicating that Adaptive Biotechnologies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vaxcyte 9 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Positive Adaptive Biotechnologies 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Is PCVX or ADPT more profitable? Vaxcyte has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -89.12%. Vaxcyte's return on equity of -23.53% beat Adaptive Biotechnologies' return on equity.Company Net Margins Return on Equity Return on Assets VaxcyteN/A -23.53% -22.20% Adaptive Biotechnologies -89.12%-64.65%-26.45% SummaryVaxcyte and Adaptive Biotechnologies tied by winning 9 of the 18 factors compared between the two stocks. Get Adaptive Biotechnologies News Delivered to You Automatically Sign up to receive the latest news and ratings for ADPT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ADPT vs. The Competition Export to ExcelMetricAdaptive BiotechnologiesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.04B$2.89B$5.35B$7.51BDividend YieldN/A1.91%5.44%4.33%P/E Ratio-6.7730.5321.9518.05Price / Sales6.13476.12396.32104.31Price / CashN/A168.6838.2034.62Price / Book5.393.716.744.14Net Income-$159.49M-$72.06M$3.21B$247.59M7 Day Performance0.68%8.74%3.96%3.51%1 Month Performance-14.78%-9.15%-7.03%-5.80%1 Year Performance183.85%-21.05%15.58%2.83% Adaptive Biotechnologies Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ADPTAdaptive Biotechnologies3.8848 of 5 stars$7.38+5.3%$9.40+27.4%+186.0%$1.04B$178.96M-6.77790Upcoming EarningsPositive NewsGap UpPCVXVaxcyte3.2518 of 5 stars$30.39-0.8%$136.50+349.2%-45.5%$3.91BN/A-6.61160Analyst ForecastAnalyst RevisionPositive NewsGap UpRYTMRhythm Pharmaceuticals4.331 of 5 stars$60.48-2.0%$74.92+23.9%+49.6%$3.82B$130.13M-13.97140News CoveragePositive NewsGap UpPTCTPTC Therapeutics3.844 of 5 stars$48.19+1.7%$63.77+32.3%+96.6%$3.80B$806.78M-8.111,410Analyst ForecastRNAAvidity Biosciences2.341 of 5 stars$28.52+7.0%$66.69+133.8%+22.0%$3.43B$10.90M-9.90190Positive NewsGap UpACLXArcellx1.8966 of 5 stars$60.93-1.8%$110.67+81.6%+16.9%$3.35B$107.94M-85.8280News CoveragePositive NewsGap UpRAREUltragenyx Pharmaceutical4.4406 of 5 stars$35.40-0.8%$92.79+162.1%-17.1%$3.32B$560.23M-5.581,310Upcoming EarningsGap UpZLABZai Lab2.8474 of 5 stars$29.71+3.0%$47.37+59.4%+122.4%$3.26B$398.99M-10.731,950Analyst RevisionNews CoveragePositive NewsGap UpAKROAkero Therapeutics4.1573 of 5 stars$37.67+0.1%$76.29+102.5%+88.8%$3.00BN/A-10.0530MRUSMerus3.0034 of 5 stars$43.23+0.4%$85.31+97.3%+2.5%$2.99B$36.13M-10.9437Positive NewsGap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730 Related Companies and Tools Related Companies Vaxcyte Competitors Rhythm Pharmaceuticals Competitors PTC Therapeutics Competitors Avidity Biosciences Competitors Arcellx Competitors Ultragenyx Pharmaceutical Competitors Zai Lab Competitors Akero Therapeutics Competitors Merus Competitors MorphoSys Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ADPT) was last updated on 4/24/2025 by MarketBeat.com Staff From Our PartnersFeds Just Admitted It—They Can Take Your CashHere’s the cold truth: If your money is sitting idle in a bank account, it’s vulnerable. That’s why thousan...Priority Gold | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredTrump Orders 'National Digital Asset Stockpile'‘Digital Asset Reserve’ for THIS Coin??? Get all the details before this story gains even more tractionCrypto 101 Media | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Exact July Date the AI Correction Will End?AI stocks have cooled off—but Jeff Brown, the tech expert who picked Nvidia before it soared 222x, says one da...Brownstone Research | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredVirtually Limitless Energy?A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptive Biotechnologies Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptive Biotechnologies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ADPT Stock Free ADPT Stock Alerts